Abstract

New onset diabetes after transplantation (NODAT) occurs less frequently in living donor liver transplant (LDLT) recipients than in deceased donor liver transplant (DDLT) recipients. The aim of this study was to compare the incidence and predictive factors for NODAT in LDLT versus DDLT recipients. The Organ Procurement and Transplant Network/United Network for Organ Sharing database was reviewed from 2004 to 2010, and 902 LDLT and 19,582 DDLT nondiabetic recipients were included. The overall incidence of NODAT was 12.2% at 1 year after liver transplantation. At 1, 3, and 5 years after transplant, the incidence of NODAT in LDLT recipients was 7.4, 2.1, and 2.6%, respectively, compared to 12.5, 3.4, and 1.9%, respectively, in DDLT recipients. LDLT recipients have a lower risk of NODAT compared to DDLT recipients (hazard ratio = 0.63 (0.52–0.75), P < 0.001). Predictors for NODAT in LDLT recipients were hepatitis C (HCV) and treated acute cellular rejection (ACR). Risk factors in DDLT recipients were recipient male gender, recipient age, body mass index, donor age, donor diabetes, HCV, and treated ACR. LDLT recipients have a lower incidence and fewer risk factors for NODAT compared to DDLT recipients. Early identification of risk factors will assist timely clinical interventions to prevent NODAT complications.

Highlights

  • New onset diabetes mellitus after transplantation (NODAT) is a serious metabolic complication with a reported incidence of 10% to 36% in liver transplant recipients [1,2,3,4,5,6,7,8]

  • Male gender, body mass index (BMI), hepatitis C virus infection (HCV), impaired fasting glucose, immunosuppressive medications, and acute cellular rejection (ACR) episodes are documented as predictive factors for NODAT

  • A total of 902 living donor liver transplant (LDLT) and 19,582 deceased donor liver transplant (DDLT) recipients were included in our study

Read more

Summary

Introduction

New onset diabetes mellitus after transplantation (NODAT) is a serious metabolic complication with a reported incidence of 10% to 36% in liver transplant recipients [1,2,3,4,5,6,7,8]. Studies suggest that NODAT in liver transplant recipients is associated with a significant increase in cardiovascular disease, infection, and decreased graft survival [6,7,8,9,10]. Male gender, body mass index (BMI), hepatitis C virus infection (HCV), impaired fasting glucose, immunosuppressive medications, and acute cellular rejection (ACR) episodes are documented as predictive factors for NODAT. The existing literature focuses on the prevalence and risk factors for NODAT in deceased donor liver transplant (DDLT) recipients [1,2,3,4,5,6]. The incidence and predictors of NODAT in living donor liver transplant (LDLT) recipients are not well established.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call